SCHEMBL305901

SCHEMBL305901

CC1COCC(=O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1005969 1.00
SCHEMBL305900 1.00
SCHEMBL2343201 0.77
SCHEMBL12391217 0.77
SCHEMBL517745 0.73 GAA (0.31)
SCHEMBL517744 0.73 GAA (0.31)
SCHEMBL13049304 0.71
SCHEMBL24631878 0.71 GAA (0.30)
SCHEMBL517616 0.71 CPB2 (0.30)
SCHEMBL1007032 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594308-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Vividion Therapeutics, Inc. (US) 2025-08-06 EP disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 US disclosed
EP-4291552-B1 MODULATORS OF COMPLEX I BOEHRINGER INGELHEIM INT (DE) 2025-04-09 EP disclosed
US-12257247-B2 Targeted degradation of VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-03-25 US disclosed
CN-119431378-A Ring-fused compound, pharmaceutical composition containing same, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2025-02-14 CN disclosed
US-12202836-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2025-01-21 US disclosed
US-20240285604-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2024-08-29 US disclosed
US-12071403-B2 Modulators of complex I BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-08-27 US disclosed
WO-2024160058-A1 OXALIC ACID DIAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 四川科伦博泰生物医药股份有限公司 2024-08-08 WO disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
US-5002937-A Diphosphonic acid alkyloxyalkylamines for bone disorders BOEHRINGER MANNHEIM GMBH (DE) 1991-03-26 US disclosed
EP-0350002-A1 Diphosphonic-acid derivatives, process for their preparation and medicines containing those compounds Roche Diagnostics GmbH (DE) 1990-01-10 EP disclosed
US-4882359-A USED WITH DRUGS HISAMITSU PHARMACEUTICAL CO., LTD. (JP) 1989-11-21 US disclosed
WO-1987006226-A2 AZACYCLOALKANE DERIVATIVES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS THE EFFECTIVE INGREDIENT AND EXTERNAL PREPARATIONS CONTAINING THE ABSORPTION PROMOTERS HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1987-10-22 WO disclosed
CN-87100666-A Nitrogen heterocyclic derivative, absorption enhancer containing the derivative as active ingredient, and external preparation containing the absorption enhancer 1987-10-21 CN disclosed
EP-0241050-A2 Azacycloalkane derivatives, absorption promoters containing the derivatives as the effective ingredient and external preparation containing the absorption promoters HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1987-10-14 EP disclosed
US-4058462-A System for sustained release of phenolic material from porous granules of insoluble polymeric phenolic complexes GAF CORPORATION (US) 1977-11-15 US disclosed
US-3985540-A Metal complexes of hydroxyquinoline and polymeric porous granules GAF CORPORATION (US) 1976-10-12 US disclosed
US-3970606-A N-vinyl lactam interpolymers useful as thickening agents GAF CORPORATION (US) 1976-07-20 US disclosed
US-3954682-A GRANULES OR BEADS GAF CORPORATION (US) 1976-05-04 US disclosed